Stifel Nicolaus Issues Positive Forecast for Zymeworks (NASDAQ:ZYME) Stock Price

Zymeworks (NASDAQ:ZYME) had its price objective boosted by Stifel Nicolaus from $40.00 to $47.00 in a report published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other research firms have also recently commented on ZYME. Wells Fargo & Company raised Zymeworks from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $25.00 to $33.00 in a report on Friday, December 12th. HC Wainwright lifted their price objective on shares of Zymeworks from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Leerink Partners upped their target price on shares of Zymeworks from $52.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday. Citizens Jmp set a $32.00 target price on shares of Zymeworks in a research note on Wednesday, December 3rd. Finally, Truist Financial began coverage on shares of Zymeworks in a research note on Wednesday, December 17th. They issued a “buy” rating and a $40.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Zymeworks presently has an average rating of “Moderate Buy” and a consensus price target of $35.70.

Zymeworks Price Performance

Shares of ZYME stock opened at $24.45 on Tuesday. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -22.64 and a beta of 1.23. The company’s fifty day moving average price is $23.85 and its 200-day moving average price is $20.95. Zymeworks has a one year low of $9.03 and a one year high of $28.49.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Zymeworks had a negative return on equity of 24.85% and a negative net margin of 76.56%.The business had revenue of $2.52 million during the quarter, compared to analysts’ expectations of $21.78 million. During the same quarter in the previous year, the company posted ($0.31) EPS. The company’s quarterly revenue was down 91.9% on a year-over-year basis.

Insider Buying and Selling at Zymeworks

In related news, COO Mark Hollywood sold 6,120 shares of Zymeworks stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $138,740.40. Following the completion of the transaction, the chief operating officer owned 132,913 shares in the company, valued at approximately $3,013,137.71. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kenneth Galbraith sold 54,343 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $25.10, for a total value of $1,364,009.30. Following the sale, the chief executive officer directly owned 158,286 shares in the company, valued at $3,972,978.60. The trade was a 25.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 187,933 shares of company stock valued at $4,673,716. Corporate insiders own 33.51% of the company’s stock.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors and hedge funds have recently modified their holdings of ZYME. Caitong International Asset Management Co. Ltd purchased a new stake in Zymeworks during the 4th quarter valued at $37,000. Seven Fleet Capital Management LP bought a new position in Zymeworks in the 4th quarter worth about $542,000. Invesco Ltd. increased its position in shares of Zymeworks by 175.0% during the fourth quarter. Invesco Ltd. now owns 257,580 shares of the company’s stock worth $6,782,000 after acquiring an additional 163,923 shares during the period. XTX Topco Ltd bought a new stake in shares of Zymeworks during the fourth quarter valued at approximately $2,461,000. Finally, VARCOV Co. bought a new stake in shares of Zymeworks during the fourth quarter valued at approximately $259,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Zymeworks News Summary

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Wall Street upgrades — Stifel raised its price target to $47 (buy) and Leerink Partners raised its target to $58 (outperform), both signaling strong analyst conviction and meaningful upside vs. the current price. Benzinga (Stifel) Benzinga (Leerink)
• Positive Sentiment: $250M non‑recourse royalty‑backed financing with Royalty Pharma provides immediate, non‑dilutive capital while preserving most future Ziihera royalties — improves flexibility to continue buybacks and pursue strategic moves. GlobeNewswire: Royalty‑Backed Financing
• Positive Sentiment: Commercial and milestone upside for Ziihera — partner Jazz is completing a supplemental BLA for first‑line HER2+ GEA (expected Q1 2026) with a potential 2H‑2026 launch; Zymeworks is eligible for up to ~$440M in GEA‑related milestones plus future royalties and further milestone pools. This underpins the company’s revenue runway and valuation re‑rating. GlobeNewswire: Corporate Update
• Positive Sentiment: Share‑repurchase execution — company has repurchased ~$62.5M under the authorized program to date; combined with the Royalty Pharma funding this supports near‑term buybacks and EPS accretion expectations. GlobeNewswire: Repurchase Details
• Neutral Sentiment: Earnings call & transcripts published — management reviewed strategy shift toward royalty/asset aggregation, R&D priorities and three‑year expense discipline; transcripts and presentations are available for detail (useful for modeling, but not new headlines). Yahoo Finance: Q4 2025 Earnings Call Summary
• Negative Sentiment: Q4 results missed expectations — reported EPS of $(0.55) vs. consensus $(0.35) and Q4 revenue of $2.52M (down sharply year‑over‑year). The weak quarterly revenue and continued GAAP losses are near‑term headwinds and warrant conservative near‑term models until royalties and milestone receipts ramp. Zacks: Q4 Loss & Revenue Miss

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.